CTIS2023-504414-29-00
Recruiting
Phase 1
Observational Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Patients with Chronic hepatitis D - SEE-D
Karolinska University Hospital0 sites400 target enrollmentMarch 6, 2023
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- hepatitis D
- Sponsor
- Karolinska University Hospital
- Enrollment
- 400
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \> 18 years, Diagnosis of chronic HBV/HDV co\-infection, Have compensated liver disease (presence of portal hypertension without ongoing hepatic decompensation, as ascites, variceal bleeding and hepatic encephalopathy, is allowed), Have indication for treatment of BLV, or already treated with BLV., For female participants: a.Postmenopausal for at least one year, or b.Surgically sterile (total hysterectomy or bilateral oophorectomy, bilateral tubal ligation, staples, or another type of sterilization), or c.Abstinence from heterosexual intercourse throughout the treatment period, or d.Willingness to use highly effective contraception (double barrier method or barrier contraception in combination with hormonal or intrauterine contraceptive) throughout the treatment period and for 6 months after last dose of the drugs in the study., Male participants must agree to use a highly effective contraception (double barrier method or barrier contraception in combination with hormonal or intrauterine contraceptive used by female partners) throughout the treatment period and for 6 months after the last dose of the drugs in the study., Participants who are willing to give written informed consent.
Exclusion Criteria
- •Any contra\-indications to treatment with BLV, including any intolerance or hypersensitivity to the active ingredient or other components of BLV., Pregnant or breast\-feeding women, Patients with predictable difficulties of FU according to the investigator, Any other condition that, in the opinion of Investigator, precludes the patient from taking part in this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Observational study to find out efficacy and safety of Bifidobacterium longum W11 plus Fructooligosaccharide combination in patients with irritable bowel syndromeHealth Condition 1: K519- Ulcerative colitis, unspecifiedCTRI/2024/07/070510Abbott India Ltd
Not yet recruiting
Phase 2
Study to assess safety and efficacy of Inj Sepsivac in patients of Covid-19CTRI/2020/05/025350R D Gardi Medical College
Not yet recruiting
Phase 3
COMPARATIVE STUDY OF THE EFFICACY AND SAFETY OF 10% RETINOL PEEL AND 70% GLYCOLIC ACID PEEL IN THE TREATMENT OF ACANTHOSIS NIGRICANSHealth Condition 1: L83- Acanthosis nigricansCTRI/2023/09/057674CHERUKUPALLI ANANTH
Not yet recruiting
Not Applicable
An observational study of Controlled Release Nitroglycerin in patients with angina.CTRI/2018/10/016215Care Lifescience Private Limited
Recruiting
Not Applicable
An observational study of the safety and efficacy of nivolumab as adjuvant treatment for esophageal cancer using the Comprehensive Registry of Esophageal Cancer in the National Clinical Database.Esophageal cancer or esophagogastric cancerJPRN-UMIN000050925Japanese Foundation For Cancer Research1,750